Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alkermes Refuse-To-File Reversal: Is It Really Good News For Anyone?

Apr 18 2018

• By Kate Rawson

Related Content

Rescinding A Refuse-To-File: A Precedent Of Sorts

Apr 18 2018

Refusal Reversal: Alkermes Review Back On Track, But Could Still Be Bumpy

Apr 17 2018

PTC’s Ataluren and Accelerated Approval: Is Eteplirsen A Precedent After All?

Mar 01 2018

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Related Companies

Alkermes plc

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

Additional Topics

United States Drug Review Drug Approval Standards FDA Neurology BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window